HIV latency reversal agents: A potential path for functional cure?

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.creatorLopes, Juliana Romano [UNESP]-
Autor(es): dc.creatorChiba, Diego Eidy [UNESP]-
Autor(es): dc.creatorDos Santos, Jean Leandro [UNESP]-
Data de aceite: dc.date.accessioned2022-02-22T00:45:22Z-
Data de disponibilização: dc.date.available2022-02-22T00:45:22Z-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-06-25-
Data de envio: dc.date.issued2021-03-05-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.ejmech.2021.113213-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/205808-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/205808-
Descrição: dc.descriptionDespite the advances in Human Immunodeficiency Virus (HIV) treatment, the cure for all HIV patients still poses a major challenge, which needs to be surpassed in the coming years. Among the strategies pursuing this aim, the ‘kick-and-kill’ approach, which involves the reactivation and elimination of a latent HIV reservoir that resides in some CD4+ T cells, appears promising. The first step of this approach requires the use of latency reversal agents (LRAs) that induce the reactivation of the latent virus. Although several classes of LRAs have been reported so far, some limitations of these compounds still need to be overcome before their clinical use. The complete exhaustion of the reservoir of latent virus will contribute to promote the second step of this approach, facilitating the elimination of the reactivated HIV. Therefore, potent, safe, and non-toxic LRAs are necessary to promote efficient elimination of the HIV-1 virus from its reservoir. In this review article, we focus on the promising LRAs that have been described in the literature over the past few years, highlighting the advantages and disadvantages of their use in the ‘kick and kill’ approach, thus opening a new avenue in the development of a potential cure.-
Descrição: dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
Descrição: dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionSão Paulo State University (UNESP) School of Pharmaceutical Sciences-
Descrição: dc.descriptionInstitute of Chemistry São Paulo State University (UNESP)-
Descrição: dc.descriptionSão Paulo State University (UNESP) School of Pharmaceutical Sciences-
Descrição: dc.descriptionInstitute of Chemistry São Paulo State University (UNESP)-
Descrição: dc.descriptionCAPES: 001-
Descrição: dc.descriptionFAPESP: 2018/11079-0-
Idioma: dc.languageen-
Relação: dc.relationEuropean Journal of Medicinal Chemistry-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectBromodomain inhibitors-
Palavras-chave: dc.subjectHistone deacetylase inhibitors-
Palavras-chave: dc.subjectHIV-
Palavras-chave: dc.subjectKick and kill approach-
Palavras-chave: dc.subjectLatency reversal agents-
Palavras-chave: dc.subjectProtein kinase C agonists-
Título: dc.titleHIV latency reversal agents: A potential path for functional cure?-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.